Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

Alembic Pharma - Solid delivery continues; Top pick BUY TP Rs 1,180 - YES Securities

Posted On: 2020-10-22 22:28:48


Q2 call takeaways

- Guidance: EPS of Rs60 for FY21 (Rs33 in H1 FY21) and Rs50/share in FY22; additional Rs4.5bn costs from new facilities in FY22. Not much in FY21 as plants to be audited by FDA.

- Domestic: Azithral oral gave a solid boost in Q2 and will continue in Q3 and Q4. Gastro and Gyanec rebounded after weakness

- Cardio, diabetes also doing well than market; only area of concern is cough and cold where IPM market still on decline and perf in line with market

- Launched 3 products in Q2 and 15 in H2 to end total of 15-20 in FY21 followed by launches from new facilities; sartans has been stable but new launches have had an offset

- General injectables pipeline is most exciting while Jarod OSD has a very large filing; onco opportunity is some time away

- Filings from F3 (onco facility) but not sure when FDA will come for physical inspection

- Rizen: Would file for CLL indication in May 2021.

Our view: A solid performance and an unprecedented EPS guidance indicates a high confidence on visibility of sustaining sartans in FY21. We bump up FY21 EPS (on back of sartans present in H2 vs earlier assumption of gradual ebb) as would the street though FY22 estimates see only a marginally uptick to Rs48 (from Rs47 earlier). Alembic stays our top BUY with unchanged TP Rs1,180. Upside risks exist to FY22 estimates if sartans continue to surprise next fiscal.

Q2 FY21 results - India sales rebound; US stays firm

- India sales surprise with 6% yoy growth after a tough Q1 which would have aided gross margin at 78% vs expected ~74%

- US sales at US$83mn continue to stay firm as sartans tailwind persists. Other expense jump 33% qoq with R&D at Rs1.8bn vs Rs1.4bn in Q1 FY21

- ROW outperforms expectation with 85% surge as base quarter was beset by serialization issues in Europe

- Solid EBIDTA performance with margins sustaining at 30%, flat qoq vs our estimated of 26.5%; PAT handily beat estimates.

Link to the report

Shares of ALEMBIC PHARMACEUTICALS LTD. was last trading in BSE at Rs.1011.6 as compared to the previous close of Rs. 997.05. The total number of shares traded during the day was 31525 in over 3223 trades.

The stock hit an intraday high of Rs. 1015 and intraday low of 980. The net turnover during the day was Rs. 31637944.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com



Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Motherson Sumi Systems - Company Update - Virtual Investor Conference - ICICI Direct

Mutual Fund Review - November, 2020 - ICICI Direct

Sadbhav Engineering - Q2FY21 Company Update - ICICI Direct

IRB Infrastructure - Q2FY21 Company Update - ICICI Direct

Vodafone Idea fund raising - Angel Broking

Rupee - Nov 23, 2020 - Reliance Securities

Crude Oil - Nov 23, 2020 - Reliance Securities

Q2FY21 Bank Result Quick Review - Angel Broking

Banks & NBFC's Sector Update Report - Yet another watershed moment? - HDFC Securities

Galaxy Surfactants - EBITDA/kg has an upside risk - ICICI Securities

Diagnostics - COVID-19 tests continue to trend higher - ICICI Securities

Banking & Financial Services - Sector Update - Nov 22, 2020 - ICICI Direct

Dalmia Bharat Sugar - Q2FY21 Company Update - ICICI Direct

Balkrishna Industries - Industry export growth momentum continues - ICICI Securities

Covid Recovery Pulse - Festive positivity continues in auto retails, E-way bill generation improves... - ICICI Direct

Quant Pick - Exide Industries - ICICI Direct

Shankara Building Products - Q2FY21 Company Update - ICICI Direct

Triveni Engineering - Q2FY21 Company Update - ICICI Direct

Initiating Coverage on Sudarshan Chemical - Leaping into the league of giants - HDFC Securities

Earnings Wrap Q2FY21: Earnings outperform, post Covid recovery picks up steam - ICICI Direct

Vodafone Idea Positive development beneficial for IDFC first bank - Angel Broking

Lakshmi Vilas Bank - Angel Broking

WIPRO Buyback record date announcement - Angel Broking

TCS buyback record date announcement - Angel Broking

Banks Sector Update - Collection efficiency - a positive surprise! - HDFC Securities

Quant Pick - Max Financial Services - ICICI Direct

Graphite India - Q2FY21 Result Update - ICICI Direct

Gladiator Stocks - Maruti Suzuki India - ICICI Direct

Exide Industries - Q2FY21 Result Update - ICICI Direct

Mishra Dhatu Nigam - Execution outlook remains strong - ICICI Securities

Bharat Electronics - Diversifying into multiple revenue streams - ICICI Securities

Wipro Ltd - Virtual Analyst Meet Update - ICICI Direct

Avadh Sugar & Energy - November 2020 - Company Update - ICICI Direct

Mahindra Lifespace Developers - H1FY21 Company Update - ICICI Direct

Quant Pick - Godrej Consumer Products - ICICI Direct

India Equity Strategy Report - Quarterly flipbook - HDFC Securities

Maintain REDUCE on Jubilant FoodWorks - Recovery continues; priced-in - HDFC Securities

Maintain BUY on Ahluwalia Contracts - Q2FY21 - Significant beat on execution - HDFC Securities

Repco Home Finance Limited - Q2 FY21 Result Update - YES Securities

JK Lakshmi Cement - Target upgrade - Angel Broking

BUY on Petronet LNG - Stellar quarter - HDFC Securities

Maintain BUY on Prestige Estates Projects - Capex cycle to gather pace - HDFC Securities

REDUCE on LIC Housing Finance - Tread with caution - HDFC Securities

SELL on New India Assurance - High claims ratio dents profits - HDFC Securities

New orders for L&T - Angel Broking

Cipla - Multi-G agreement - Angel Broing

REDUCE on Eicher Motors - 'Meteor' to drive sales; valuations remain expensive - HDFC Securities

BUY on Galaxy Surfactants - Highest volumes in a quarter - HDFC Securities

Repco Home Finanance - Q2FY21 Result - Angel Broking

NMDC - A single headwind against investment thesis - II - ICICI Securities



Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019